Login
$MXCT
$1.18 -$0.01 (0.84%) Live

$MXCT SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

Exhibit E – Form of Akron BioManufacturing Release Agreement

02 Nov 2026 SCHEDULE 13D
15 Oct 2026 SCHEDULE 13D
14 Oct 2026 8-K: Results of Operations and Financial Condition

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026

13 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue

04 Aug 2026 SCHEDULE 13D
29 Jul 2026 SCHEDULE 13G/A
22 Jun 2026 Form 4: Johnston John Joseph, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Hemrajani Rekha, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Erck Stanley C, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Douglas Richard, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Collins Cynthia, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Brooke William W, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Balthrop Patrick J, Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

22 Jun 2026 Form 4: Al-Wakeel Yasir B., Director

Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

At the 2026 annual meeting of stockholders of MaxCyte, Inc. (the “Company”) held on June 17, 2026 (the “Annual Meeting”), the Company’s stockholders considered and approved two proposals, each of which is described in more detail in the ...

16 Jun 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Na...

14 May 2026 SCHEDULE 13D

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support